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Abstract
Background: Hypertriglyceridemia (HTG) is a well-established independent risk factor for cardiovascular disease and 
the influence of several genetic variants in genes related with triglyceride (TG) metabolism has been described, 
including LPL, APOA5 and APOE. The combined analysis of these polymorphisms could produce clinically meaningful 
complementary information.
Methods: A subgroup of the ICARIA study comprising 1825 Spanish subjects (80% men, mean age 36 years) was 
genotyped for the LPL-HindIII (rs320), S447X (rs328), D9N (rs1801177) and N291S (rs268) polymorphisms, the APOA5-
S19W (rs3135506) and -1131T/C (rs662799) variants, and the APOE polymorphism (rs429358; rs7412) using PCR and 
restriction analysis and TaqMan assays. We used regression analyses to examine their combined effects on TG levels 
(with the log-transformed variable) and the association of variant combinations with TG levels and 
hypertriglyceridemia (TG ≥ 1.69 mmol/L), including the covariates: gender, age, waist circumference, blood glucose, 
blood pressure, smoking and alcohol consumption.
Results: We found a significant lowering effect of the LPL-HindIII and S447X polymorphisms (p < 0.0001). In addition, 
the D9N, N291S, S19W and -1131T/C variants and the APOE-ε4 allele were significantly associated with an independent 
additive TG-raising effect (p < 0.05, p < 0.01, p < 0.001, p < 0.0001 and p < 0.001, respectively). Grouping individuals 
according to the presence of TG-lowering or TG-raising polymorphisms showed significant differences in TG levels (p < 
0.0001), with the lowest levels exhibited by carriers of two lowering variants (10.2% reduction in TG geometric mean 
with respect to individuals who were homozygous for the frequent alleles of all the variants), and the highest levels in 
carriers of raising combinations (25.1% mean TG increase). Thus, carrying two lowering variants was protective against 
HTG (OR = 0.62; 95% CI, 0.39-0.98; p = 0.042) and having one single raising polymorphism (OR = 1.20; 95% CI, 1.39-2.87; 
p < 0.001) or more (2 or 3 raising variants; OR = 2.90; 95% CI, 1.56-5.41; p < 0.001) were associated with HTG.
Conclusion: Our results showed a significant independent additive effect on TG levels of the LPL polymorphisms 
HindIII, S447X, D9N and N291S; the S19W and -1131T/C variants of APOA5, and the ε4 allele of APOE in our study 
population. Moreover, some of the variant combinations studied were significantly associated with the absence or the 
presence of hypertriglyceridemia.
Background
The underlying determinants of individual susceptibility
to cardiovascular disease (CVD) form a complex network
of interactions between genetic and environmental risk
factors, as a consequence of their multi-factorial nature
[1]. Changes in triglyceride (TG) levels are now consid-
ered an independent cardiovascular risk factor [2,3];
hence, the study of combined variants in genes involved
in TG metabolism may help explain part of the risk for
CVD [4].
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The influence of LPL, APOA5 and APOE genes on TG
metabolism is well established. These genes code for pro-
teins which are simultaneously present during the lipoly-
sis of the TG core of circulating chylomicrons and VLDL.
Lipoprotein lipase is the major TG-hydrolyzing enzyme
[5], apolipoprotein AV has emerged as a regulator of TG
levels by improving lipolysis efficiency [6-8] and apolipo-
protein E, in addition to its critical role in receptor-medi-
ated remnant clearance (liver uptake of TG-rich
lipoproteins), is directly involved in lipolysis [9,10].
Numerous sequence variants have been described in all
three of these genes. In LPL, D9N and N291S induce
amino acid changes leading to lower post-heparin plasma
LPL activity, affecting enzyme secretion or destabilizing
homodimer complex formation, respectively. Both poly-
morphisms have been associated with increased plasma
TG concentrations and with ischemic heart disease
[11,12]. Inversely, the HindIII variant, which seems to be
located within a regulatory element in intron 8 of the LPL
gene [13], has been related with a protective effect [14].
Moreover, the nonsense polymorphism S447X has been
associated with a gain of activity because of the prema-
ture truncation of the enzyme [15]. Consequently, it has
also been related with lower fasting TG levels [14] and,
very recently, with a favourable influence on the longitu-
dinal changes of these levels [16]. The most informative
polymorphisms within the APOA5 gene are the S19W
missense polymorphism and the -1131T/C promoter
variant, which define the initially described APOA5 hap-
lotypes [17]. Both these polymorphisms have been asso-
ciated with changes in T G levels in many populations,
even with severe hypertriglyceridemia (HTG), as well as
with CVD [18]. Genetic associations between the com-
mon APOE gene alleles, ε2, ε3 and ε4, and susceptibility
to CVD and changes in cholesterol levels have been well
replicated; however, disagreement still exists concerning
APOE polymorphism and changes in TG concentrations
[19].
The effects of each common variant involved in the
expression of a multi-factorial trait are assumed to be
modest and depend, at least in part, on differences in the
environmental and the genetic context within the vari-
ants analyzed [20]. Therefore, the joint analysis of com-
mon functional variants of these genes, which have so far
only been studied separately in many populations, might
be important to better explain changes in TG levels.
We therefore determined the allele frequencies of four
LPL  variants (HindIII, S447X, D9N and N291S), two
APOA5 variants (S19W and -1131T/C) and the APOE
polymorphism (alleles ε2, ε3, ε4) in a large Mediterranean
working population and assessed their combined effect
on TG levels. Additionally, we studied the association
between the presence of variant combinations (TG-low-
ering or TG-raising, or both) and TG levels and HTG.
Methods
Subjects
This work forms part of Ibermutuamur's Cardiovascular
Risk Prevention Project [21,22] in which Spanish active
workers, insured by this mutual insurance fund, were
screened for cardiovascular risk factors at their annual
medical check-up (MCU). The study conformed to the
current Helsinki declaration and was reviewed and
approved by Ibermutuamur's scientific Ethics Commit-
tee. The data presented here correspond to 1825 workers
(1460 men and 365 women) from Malaga, a city on the
Mediterranean coast of southern Spain, who attended for
their routine MCU between 2004 and 2005 and gave
written informed consent to participation in the study.
The exclusion criteria were to be on sick leave and not
signing the informed consent.
All the participants provided information about their
date of birth, gender, profession, medication, smoking
and alcohol consumption. Data on risk factors (diabetes,
hypertension and cardiovascular diseases) were captured
by medical record assessment following previously
defined criteria [21]. The MCU included data on weight,
height, waist circumference and blood pressure, as
described [21]. Biochemical analyses were made from 12-
hour fasting serum samples in Ibermutuamur's reference
laboratories, using standard protocols. Participants were
considered to be smokers if they smoked at the time of
data collection or had quit smoking less than one year
before. Regarding alcohol consumption, they were cate-
gorized as daily users versus occasional or non users.
HTG was considered to be present if the fasting serum
triglycerides ≥ 1.69 mmol/L [23].
DNA extraction and genotyping
Genomic DNA was isolated from frozen EDTA whole
blood using a BioRobot®  EZ1 (QIAGEN, Hilden, Ger-
many) with the corresponding reagents. All PCR reac-
tions needed for genotyping were carried out in a thermal
cycler iCycler iQ™ (BioRad, California, USA). APOE
(rs429358, rs7412) and HindIII (rs320) genotypes were
determined by PCR and restriction fragment analysis
using the iQ™ SYBR Green Supermix. The APOE amplifi-
cation products were digested with HhaI following the
manufacturer's instructions (Takara, Japan) and the
resulting fragments separated on 4% agarose gel. Frag-
ments corresponding to samples initially genotyped as ε2
carriers were also separated on 8% polyacrylamide gels to
clearly distinguish between ε2ε2 and ε2ε3 genotypes. The
digestion products obtained for the HindIII polymor-
phism were separated on 3.5% agarose gels. LPL (S447X -
rs328-, N291S -rs268- and D9N -rs1801177-) and APOA5
(S19W -rs3135506- and -1131T/C -rs662799-) variants
were determined by TaqMan assays using the iQ™ Super-
mix and the allele discrimination mode of the iQ™ soft-Ariza et al. BMC Medical Genetics 2010, 11:66
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ware. The primer and probe sequences as well as the
thermal protocols used in the PCR reactions are pre-
sented in the Additional file 1. The quality of genotyping
was controlled using DNA samples of known genotypes,
retyping those samples with an ambiguous band pattern
on the same assay (for APOE  and HindIII polymor-
phisms) and those with no interpretable optical PCR data
(TaqMan assays) using PCR and restriction, and duplicat-
ing genotypes in 10% of randomly selected samples. The
genotype error rate was estimated to be <1%.
Statistical analyses
The statistical analyses were done using SPSS, version
14.0 for Windows and R [24]. A p value < 0.05 was consid-
ered statistically significant. Allele frequencies were cal-
culated by direct counting. The SNPassoc package from
R [25] was used to obtain the exact p values to verify
Hardy-Weinberg equilibrium, to obtain measures of link-
age disequilibrium and to check the validity of classifying
individuals as carriers (heterozygous and homozygous for
the minor allele) or non-carriers (homozygous for the fre-
quent alleles) of each genetic variant that implies domi-
nance between alleles. The TG variable was log-
transformed to improve normality. The results were
finally expressed in the original scale, after exponentia-
t i o n  o f  t h e  a d j u s t e d  l e a s t - s q u a r e  m e a n s ,  a s  g e o m e t r i c
means and the corresponding asymmetric 95% confi-
dence intervals. The ANOVA or the Student t tests were
used to compare log-TG means between groups. Differ-
ences between genders were assessed using the Student t
test to compare means of continuous variables, the
Mann-Whitney U test to compare ordinal variables and
the χ2 test to compare percentages. When the expected
values in more than 20% of cells were less than 5, Fisher's
exact test was applied. A multivariate linear regression
model with dummy variables for categorical terms was
elaborated to test the null hypothesis of no association
between each genetic variant assessed and log-TG,
adjusting for the covariates: gender, age, waist circumfer-
ence, blood glucose, blood pressure, smoking and alcohol
consumption. Because of this logarithmic transforma-
tion, B coefficients associated with variant effects were
multiplicative. We assessed, one at time, the significance
of the two-factor interaction terms between variants. The
critical p value after Bonferroni correction for multiple
comparisons was 0.003. Logistic regression models were
constructed to calculate the odds ratios for developing
HTG associated with the presence of TG-lowering or
TG-raising variants with respect to having no altering
alleles (homozygous for the frequent alleles), adjusting for
covariates. Standard regression diagnostic methods such
as multicolinearity tests, the homogeneity of variance test
and normal plots of the residuals were used to ensure the
appropriateness of the models.
Results
The main features of the study population are shown in
Table 1. As found in the whole ICARIA study [21], men
represented the majority of subjects (80%) and differed
from women in the main biochemical and clinical vari-
ables analyzed. The prevalence of HTG (TG ≥ 1.69 mmol/
L) was 22.8% (26.9% in men, 6.6% in women); only one
man had TG > 11.29 mmol/L.
Allele frequencies
All subjects were genotyped for the polymorphisms sum-
marized in the text. Table 2 shows the genotype distribu-
tion and allele frequencies. Our population was in Hardy-
Weinberg equilibrium for all variants analyzed. The high-
est frequencies of the rare variants of polymorphisms
corresponded to the LPL-HindIII H- allele (29%) and to
LPL-447X (12%) and the lowest frequencies to the LPL-
9N (1.6%) and 291S (1.5%) alleles. The two APOA5 vari-
ants had similar allele frequencies (19W, 6.8%; -1131C,
6.2%) and the APOE alleles were, from the most to least
frequent, ε3, ε4 and ε2, respectively. We found a strong
linkage disequilibrium between the LPL-HindIII and
S447X polymorphisms (D'= 0.984, r2 = 0.308, P < 0.0001).
Associations between gene variants and TG levels
Table 3 shows TG geometric means and 95% confidence
intervals (CI) according to the genotypes of the polymor-
phisms analyzed. These results confirm the lowering
effect on TG levels of LPL-HindIII and S447X polymor-
phisms. In contrast, the presence of LPL-D9N, and the
APOA5  -S19W and -1131T/C variants was associated
with higher TG concentrations. Carriers of the LPL-
N291S polymorphism showed a non-significant trend for
higher levels of TG than non-carriers. Moreover, signifi-
cant differences were also seen in TG levels between the
APOE genotypes.
To elaborate the linear regression model, subjects were
classified as carriers and non-carriers of the rare allele. In
the case of APOE polymorphism, we grouped individuals
as ε4 carriers (ε4ε4, ε3ε4 and ε2ε4) versus non-carriers
and ε2 carriers (ε2ε2, ε2ε3 and ε2ε4) versus non-carriers.
The ε4 carriers showed significantly higher TG levels
(geometric mean 1.24 mmol/L; 95% CI: 1.16-1.32) than
non-carriers (geometric mean 1.11 mg/dL; 95% CI: 1.06-
1.13; P = 0.001). However, the ε2 carriers showed no sig-
nificant differences in TG levels as compared with non-
carriers. Similar results were obtained after excluding
ε2ε4 subjects.
I n  o r d e r  t o  a v o i d  c o - l i n e a r i t y  i n  r e g r e s s i o n  a n a l y s e s,
individuals with the LPL-HindIII and S447X polymor-
phisms were classified into three groups: 1) those who did
not carry either HindIII or S447X (no protective variant),
2) carriers of either HindIII or S447X (one protective
variant) and 3) carriers of both polymorphisms (two pro-Ariza et al. BMC Medical Genetics 2010, 11:66
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tective variants). The genotypes included in each group
as well as their corresponding TG geometric means and
the 95% confidence intervals are specified in Table 4. As
can be seen, 99% of the subjects with one protective vari-
ant were carriers of the HindIII H- rare allele but not the
447X.
As shown in Table 5, after adjustment for the covariates
(gender, age, waist circumference, blood glucose, blood
pressure, smoking and alcohol use) the multiple regres-
sion model confirmed a significant TG-lowering effect of
combined polymorphisms previously considered protec-
tive (when dummy variables evaluating HindIII or S447X
separately were introduced in the model both reached
statistical significance). Moreover, in our population, the
LPL-D9N and LPL-N291S, and the APOA5-S19W,
APOA5- (-1131T/C) variants and the APOE-ε4 allele
were significantly associated with an independent addi-
tive TG-raising effect. Of all the variants analyzed, only
the APOE-ε2 allele was not associated with changes in
TG levels.
As no significant heterogeneity of the effect of any vari-
ant was detected according to gender, the remainder of
the analyses were done for the group as a whole. More-
over, the corresponding interaction terms between vari-
ants were all far from reaching statistical significance.
Table 1: Anthropometric, biochemical and life-style features of the study subjects.
Total (n = 1825) Women (n = 365) Men (n = 1460) 4p
Age (years)1 36 ± 10 34 ± 8 37 ± 10 <0.001
BMI (Kg/m2)1 27.0 ± 5.0 24.5 ± 5.0 28.6 ± 4.7 <0.001
Waist circumference (cm)1 92.1 ± 12.3 82.1 ± 11.0 94.3 ± 11.2 <0.001
Total cholesterol (mmol/L)1 5.16 ± 1.06 5.01 ± 0.89 5.20 ± 1.09 0.001
LDL cholesterol (mmol/L)1 3.27 ± 0.87 3.11 ± 0.74 3.31 ± 0.90 <0.001
HDL cholesterol (mmol/L)1 1.28 ± 0.31 1.48 ± 0.32 1.23 ± 0.28 <0.001
Non-HDL cholesterol (mmol/L)1 3.88 ± 1.01 3.53 ± 0.82 3.97 ± 1.04 <0.001
TG (mmol/L)2 1.12 (1.09-1.15) 0.83 (0.79-0.87) 1.21 (1.17-1.24) <0.001
Blood glucose (mmol/L)1 4.88 ± 1.17 4.50 ± 0.50 5.00 ± 1.22 <0.001
Systolic blood pressure 
(mmHg)1
126 ± 17 113 ± 13 129 ± 16 <0.001
Diastolic blood pressure 
(mmHg)1
75 ± 12 71 ± 9 75 ± 12 <0.001
Smokers3 889 (49%) 158 (43%) 731 (50%) 0.015
Alcohol consumption3 326 (18%) 13 (3.6%) 313 (21%) <0.001
Type 2 diabetes mellitus3 22 (1.2%) 1 (0.3%) 21 (1.4%) 0.102
CVD3 9 (0.56%) 0 (0%) 9 (0.7%) 0.369
Lipid lowering agent users3 28 (1.6%) 2 (0.6%) 26 (1.8%) 0.091
Cardiovascular risk SCORE3 <0.001
Low 1647 (94.2%) 350 (98.9%) 1297 (93%)
Medium 15 (0.9%) 0 (0%) 15 (1.1%)
High 86 (4.9%) 4 (1.1%) 82 (5.9%)
Type of employement3 <0.001
Agriculture 6 (0.3%) 0 (0%) 6 (0.4%)
Manufacturing 173 (9.8%) 29 (8.4%) 144 (10.2%)
Construction 684 (38.8%) 55 (15.9%) 629 (44.4%)
Services 902 (51.1%) 263 (75.8%) 639 (45.1%)
1 Variables expressed as means ± standard deviations.
2 Variable expressed as geometric mean and 95% confidence interval
3 Variables expressed as number of individuals and percentages.
4 p value for the comparison between women and men.
LDL-C was calculated by the Friedewald formula for samples with TG < 4.52 mmol/L (n = 1799)Ariza et al. BMC Medical Genetics 2010, 11:66
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Analysis of variant combinations
The joint analysis of the polymorphisms revealed the
presence of 46 different variant combinations, shown in
the Additional file 2. Taking into account the low fre-
quency of some of these and considering that the linear
regression model indicated an independent effect of the
polymorphisms, the subjects were grouped according to
the presence of TG-lowering (L) and/or TG-raising (R)
v a r i a n t s ,  a s  f o l l o w s :  ( a )  c a r r i e r s  o f  b o t h  H i n d I I I  a n d
S447X (2L); (b) carriers of HindIII and S447X polymor-
phisms and any TG-raising variant (2L and R); (c) carriers
of HindIII or S447X (1L); (d) subjects homozygous for the
frequent alleles of the polymorphisms (No variant, NV);
(e) carriers of one protective variant and any TG-raising
polymorphism (1L and R); (f) carriers of one single TG-
raising variant (1R), and (g) carriers of combinations of
two or three TG-raising polymorphisms (2-3R). Due to
their genotype frequencies (Table 4), 99% of the subjects
in groups (c) and (e) were carriers of the HindIII poly-
morphism. No significant association was found between
any of the seven groups and waist circumference, glycae-
mia, blood pressure, age, gender, smoking or alcohol con-
sumption.
Table 2: Genotype distribution and allele frequencies of the LPL, APOA5 and APOE variants.
Gene Variant Reference
sequence
Genotype distribution
n (%)
Allele
frequencies
p1
LPL Hind III rs320 H+H+ 920 (50.41) H+ 0.708 0.749
H+H- 743 (40.71) H- 0.292
H-H- 162 (8.88)
LPL S447X rs328 447SS 1431 (78.41) 447S 0.884 0.470
447SX 364 (19.95) 447X 0.116
447XX 30 (1.64)
LPL D9N rs1801177 9DD 1768 (96.88) 9D 0.984 0.722
9DN 56 (3.07) 9N 0.016
9NN 1 (0.05)
LPL N291S rs268 291NN 1771 (97.04) 291N 0.985 0.892
291NS 54 (2.96) 291S 0.015
291SS 0 (0.00)
APOA5 S19W rs3135506 19SS 1585 (86.85) 19S 0.932 0.982
19SW 231 (12.66) 19W 0.068
WW 9 (0.49)
APOA5 -1131T/C rs662799 -1131TT 1609 (88.16) -1131T 0.938 0.479
-1131TC 206 (11.29) -1131C 0.062
-1131CC 10 (0.55)
APOE C112R rs429358 ε2ε2 4 (0.22) ε2 0.057 0.741
R158C rs7412 ε2ε3 181 (9.92) ε3 0.847
ε3ε3 1312 (71.89) ε4 0.096
ε3ε4 287 (15.73)
ε4ε4 22 (1.21)
ε2ε4 19 (1.04)
1Exact p value for Hardy-Weinberg equilibriumAriza et al. BMC Medical Genetics 2010, 11:66
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Figure 1 shows the differences in TG levels of the vari-
ant combinations with respect to the "no variant" group,
considered as the reference group. The greatest differ-
ences corresponded to carriers of two protective variants,
with a 10.2% reduction in the TG geometric mean, and to
carriers of two or three TG-raising polymorphisms, with
a 25.1% increase in TG. Regarding the odds ratios (OR)
for HTG (Figure 2), the presence of two TG-lowering
polymorphisms was significantly associated with a pro-
tective effect (2L; OR = 0.62; 95% CI, 0.39-0.98, p  =
0.042). Conversely, groups of single TG-raising variants
(1R; OR = 1.20; 95% CI, 1.39-2.87, p < 0.001) or more than
one TG-raising polymorphisms (2-3R; OR = 2.90; 95% CI,
1.56-5.41, p < 0.001) were significantly associated with
HTG. This association disappeared in combinations with
protective variants (non significant OR for groups "2L
and R" and "1L and R").
Discussion
Our study describes for the first time the simultaneous
analysis of the genetic variants HindIII, S447X, D9N and
N291S (LPL), S19W and -1131T/C (APOA5) and the
APOE polymorphism and their association with TG lev-
els in a large, well-characterized Spanish Mediterranean
population. The results clearly show an independent
effect of the polymorphisms studied, TG-lowering in the
Table 3: Triglyceride geometric means and 95% confidence intervals (mmol/L) by LPL, APOA5 and APOE genotypes.
LPL-S447X1 447SS 1.15 (1.12-1.19) APOA5-S19W4 19SS 1.11 (1.07-1.14)
447SX 1.02 (0.96-1.07)6 19SW 1.19 (1.10-1.28)
447XX 0.90 (0.75-1.10) 19WW 1.92 (0.94-3.96)9
LPL-HindIII1 H+H+ 1.17 (1.13-1.22) APOA5- (-1131T/C)5 -1131TT 1.11 (1.07-1.14)
H+H- 1.07 (1.03-1.11)7 -1131TC 1.24 (1.15-1.33)
H-H- 1.04 (0.97-1.13)8 -1131CC 1.39 (0.98-1.95)10
LPL-D9N2 9DD 1.12 (1.08-1.14) APOE1 ε2ε2 0.62 (0.35-1.10)
9DN 1.25 (1.07-1.47) ε2 ε3 1.19 (1.03-1.29)
9NN 3.56 ε3ε3 1.08 (1.05-1.12)
LPL-N291S3 291NN 1.12 (1.08-1.14) ε3ε4 1.22 (1.14-1.30)11
291NS 1.28 (1.11-1.46) ε4ε4 1.50 (1.17-1.92)
291SS - ε2ε4 1.00 (0.80-1.26)
Significant differences of ANOVA or the Student t test using log transformed variable (1p < 0.001; 2p = 0.043; 3p = 0.080; 4p = 0.005; 5P = 0.012).
Significant differences (p < 0.05) of post-hoc Bonferroni analysis: 6compared with 447SS; 7,8compared with H+H+; 9compared with 19SS and 
19SW; one man TG>11.29 mmol/L; 10compared with -1131TT; 11compared with ε3ε3.
Table 4: Genotype distribution according to the presence of LPL HindIII and/or S447X polymorphisms.
Protective variants Genotypes TG1
No (N = 916) H+H+447SS (n = 916) 1.17 (1.13 - 1.22)
One (N = 519) H+H-447SS (n = 459) 1.11 (1.06 - 1.16)
H-H-447SS (n = 56)
H+H+447SX (n = 4)
Two (N = 390) H+H-447SX (n = 284) 1.00 (0.95 - 1.06)2
H-H-447SX (n = 76)
H-H-447XX (n = 30)
H+ represents the most frequent allele of the HindIII variant and H- the least frequent allele. 1Geometric means (mmol/L) and 95% confidence 
intervals. p < 0.0001 of ANOVA test. 2Significantly different as compared to groups carrying one or no protective variant.Ariza et al. BMC Medical Genetics 2010, 11:66
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case of HindIII and S447X and with a clear TG-raising
effect in the case of the D9N, N291S, S19W and -1131T/
C variants and the APOε4 allele. Thus, combinations of
lowering and/or raising polymorphisms showed a TG
gradient below or above the TG levels of the reference (no
variant) group. Moreover, the variant combination con-
sisting of two lowering polymorphisms was protective
against HTG, whereas having single or combined TG-
raising variants was independently associated with HTG.
The frequency of carriers of LPL-D9N and N291S poly-
morphisms was around 3%, i.e., between the 1% and 7%
described for healthy Caucasian persons [26,27], though
no studies have, as far as we are aware, been carried out in
Mediterranean populations of this size. We have only
been able to find one Mediterranean study, that of
Choumeriannou et al. [28], which showed a similar fre-
quency (3.6%) for the LPL-N291S variant in a group of 84
Greek patients with familial hypercholesterolaemia. We
have found no population studies in our area with which
to compare the frequency of the D9N polymorphism and
the allele frequency data presented is therefore original
for this variant. The minor allele frequencies of APOA5-
S19W and -1131T/C variants (6.2% and 6.8%, respec-
tively) were similar to those of Caucasians elsewhere
[17,29] and similar to those recently described in the
Spanish EPIGEM population [30]. The protective LPL
variants HindIII and S447X, and the APOE  polymor-
phism have been studied in our country [14,31] and were
found to be within the range reported for other popula-
tions from southern Europe [32,33].
Our work confirms the associations found in previous
studies between the gene variants studied and TG levels
[12,18,27,31], though it is the first time they have been
analyzed simultaneously and in a large population,
thereby showing their individual independent effect.
Assuming a modest role of single polymorphisms as
markers of complex diseases the study of variant combi-
nations provides complementary information that could
be clinically meaningful. Recent studies on genetic pre-
disposition to CVD reinforce this idea as they show that
certain polymorphism combinations, including variants
in genes analyzed in our work, can predict CVD [4,34].
Table 5: Multiple linear regression model for the association between variants and TG levels adjusting for covariates.
Variable B1 95% confidence interval p value
LPL-protective variant 
combination2
0.920 0.895 - 0.947 <0.0001
LPL-D9N3 1.142 1.000 - 1.303 0.048
LPL-N291S3 1.198 1.048 - 1.369 <0.01
APOA5-S19W3 1.128 1.054 - 1.206 <0.001
APOA5- (-1131T/C)3 1.154 1.075 - 1.239 <0.0001
APOE-ε23 1.038 0.966 - 1.115 0.309
APOE-ε43 1.109 1.045 - 1.176 <0.001
Statistical analysis was performed excluding one subject with TG > 11.29 mmol/L and those taking lipid lowering drugs (n = 1731). R2 of the 
model 0.30.
1Multiplicative coefficient of the effect of each variant, obtained after undoing logarithmic transformation.
2One protective variant or two protective variants versus reference (no protective variants).
3Carriers of the minor allele (homozygous and heterozygous) versus reference (homozygous for the frequent allele)
Figure 1 Differences in TG geometric means and 95% confidence 
intervals for the groups of variant combinations. The absolute val-
ues of the differences with respect to the NV group (no variant, i.e. ho-
mozygous for the frequent alleles of the polymorphisms) are given in 
mmol/L. The differences are expressed as percentages at the bottom 
of the figure. L: TG-lowering; R: TG-raising. p < 0.0001 for the mean 
comparisons using the ANOVA test.
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The results of our study show that the most favourable
variant combination consisted of the presence of just TG-
lowering variants of LPL and the least favourable was the
presence, with no protective alleles, of at least one TG-
raising variant. These results are in agreement with those
of previous studies analyzing combinations of LPL vari-
ants [12] or combinations of LPL and APOC3 [14]. Addi-
tionally, our data suggest that the protective effect of
HindIII and S447X is retained, not only versus the vari-
ants of LPL [12] but also versus those of APOA5 and
APOE, which is a novel aspect of our study.
A recent report dealing with a Czech cohort forming
part of the MONICA study [35] found that the raising
effect of the APOA5 variants (-1131T/C or S19W) was
significant in females but in males a non-significant trend
was observed. Moreover, APOA5 did not affect plasma
TG levels if the APOE-ε4 allele was present. Our results
differ, as we clearly found an additive and independent
effect of these variants of APOA5 and the other polymor-
phisms studied, with no heterogeneity according to gen-
der. The lack of effect described by Hubacek et al is
controversial, as previous results from the same group
showed an increased frequency of the APOA5-
19W*APOE-ε4 combination in persons with severe HTG
as compared with a healthy population [36]. Sousa et al
[37] have also described an interaction for the risk of
developing severe HTG associated with the combination
APOA5-1131C*APOE-ε2. In our study, however, we did
not find a main TG-raising effect associated with the
APOE-ε2 allele; conversely, this lack of association with
TG levels has been described in other populations for the
APOE-ε4 allele [38,39]. On other hand, the higher TG
levels seen by us in APOA5*APOE  and other variant
combinations were not significantly associated with an
interaction effect. It is important to note the differences
between these studies regarding their design (case-con-
trol, population-based,...) and in terms of the statistical
approach (univariate or regression analyses, different
covariates used,...), and there may also be situations of
limited statistical power. Finally, a major consideration is
that the differences in the environmental and genetic
context of the populations studied may strongly influence
the results obtained and thus explain the lack of concor-
dance among these studies.
As expected, the presence of a TG-raising polymor-
phism, and even more so that of a combination of these
variants, was associated with a greater likelihood of HTG,
as Figure 2 clearly shows. Prior analyses by another group
[38] have shown an increase in the OR with effect from
two TG-raising variants, depending on the waist circum-
ference; indeed, the effect was amplified when the num-
ber of TG-raising polymorphisms rose together with the
presence of abdominal obesity. This contrasts with data
from the present study, since the association with HTG
with effect from one TG-raising variant was independent
of waist circumference. The combined analysis of the TG-
lowering and TG-raising variants, which is original to this
study, partly explains these differences, as the TG-lower-
ing polymorphisms were not analysed in the study by
Brisson et al. As can be seen in Figure 2, the association
of the TG-raising variants with HTG lost its significance,
even with just one protective variant, i.e. with the LPL-
HindIII intronic polymorphism. Therefore, our results
reinforce the concept that this polymorphism has a mod-
estly advantageous effect independent of the S447X vari-
ant (in linkage disequilibrium with it and classically
considered functional) and highlight the importance of
analyzing both protective variants.
Finally, the association of the APOA5 polymorphisms
S19W and -1131T/C, and the APOE  non-ε3 genotype
with severe HTG has been recently reported [40]. This
report also highlights the multiplicative effect in the value
of the Odds Ratios for severe HTG of combinations of six
TG-raising polymorphisms, always with one of the
APOA5 variants. Unfortunately, despite the fact that our
study population was large, the relatively small number of
persons with TG-raising combinations and with HTG
limits the statistical power to detect certain potential
interactions between variants.
Although our study supports previous results from
other groups and provides new findings with consistent
results, certain limitations are involved. Firstly, it is obvi-
ous that the characteristics inherent to the study popula-
Figure 2 Odds Ratios for hypertriglyceridaemia associated with 
the variant combinations. NV: no variant, considered as the reference 
group. L: TG-lowering; R: TG-raising. HTG defined as TG levels ≥ 1.69 
mmol/L.
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tion (geographical area, age, state of health) condition the
results obtained. Secondly, analysis of more variants in
more genes as well as other environmental variables [41],
such as diet and physical activity, not assessed in our
study might likely better explain variability in TG levels
and the manifestation of HTG.
Conclusion
This work, carried out in a subpopulation of 1825 sub-
jects of the ICARIA study, revealed an independent and
additive effect of the polymorphisms HindIII, S447X,
D9N and N291S of LPL, S19W and -1131T/C of APOA5
and the ε4 allele of APOE on TG levels. Combinations of
TG-lowering (HindIII/S447X) and/or TG-raising variants
(the other polymorphisms) were related to different TG
levels and, as a consequence, some of these variant com-
binations were significantly associated with the absence
(2 TG-lowering polymorphisms) or the presence (one or
more TG-raising variants) of HTG. Because serum TG
are markedly associated with vascular disease in the
ICARIA population [3], the follow-up of our cohort may
shed light on the association between genetic variant
combinations and new vascular disease.
Acknowledgements
This work was partially supported by a grant of the Span-
ish Atherosclerosis Society (Beca FEA/SEA 2006 para
Investigación Clínico-Epidemiológica) and by the
Andalusian Government (Ayuda de Investigación a la
Unidad de Investigación de Lípidos y Ateriosclerosis
CTS157 convocatoria 2007).
The authors would like to thank Guadalupe Requena-
Santos (MD), Martha Cabrera-Sierra (MD), Juan Carlos
Sáinz-Gutiérrez (MD) and Montserrat Ruiz-Moraga for
their contribution in clinical data capture and manage-
ment. We also thank Ian Johnstone for his help with the
English language version of the manuscript.
Additional material
Competing interests
A non-financial competing interest is declared, related to the genotyping work,
as three patent applications have been applied for:
• Ariza MJ, Rioja J, Valdivielso P, Sánchez-Chaparro MA and González-San-
tos P. Set of primers, probes, procedure and kit for the genotyping of the
APOA5 genetic polymorphism S19W. N°: P200802183.
• Ariza MJ, Rioja J, Valdivielso P, Sánchez-Chaparro MA and González-San-
tos P. Set of primers, probes, procedure and kit for the genotyping of the
APOA5 genetic polymorphism -1131T/C. N°: P200802184.
• Ariza MJ, Rioja J, Valdivielso P, Sánchez-Chaparro MA and González-San-
tos P. Set of primers, probes, procedure and kit for the genotyping of the
LPL genetic polymorphism S447X. N°: P200802182.
Authors' contributions
MJA coordinated and participated in genotyping, participated in the analysis
of the data and wrote the first draft. MASC coordinated the scientific design of
the ICARIA project and the local recruitment of subjects and clinical data cap-
ture. FJB conducted the statistical analyses and elaborated the vectorial format
of figures. AMH carried out most of the practical work (sample processing, DNA
extraction and genotyping). ECB coordinated the computer and statistical
applications of the ICARIA project. JAG, coordinated the medical teams of the
ICARIA project. ECB and JAG assisted in the recruitment of subjects and clinical
data capture. JR assisted in practical work and provided critical revisions of the
manuscript. PV revised the manuscript critically for important intellectual con-
tent; PGS conceived, designed and coordinated the study. All authors have
contributed to and approved the final version of the manuscript.
Author Details
1Departamento de Medicina y Dermatología, Facultad de Medicina, 
Laboratorio de Lípidos y Arteriosclerosis, Centro de Investigaciones Médico-
Sanitarias (CIMES), Universidad de Málaga, Campus de Teatinos, 29010 Málaga, 
Spain, 2Ibermutuamur Cardiovascular Risk Assessment (ICARIA) Study Group, 
Ibermutuamur: Mutua de Accidentes de Trabajo y Enfermedades Profesionales 
de la Seguridad Social n° 274, 28043 Madrid, Spain, 3Departamento of 
Medicina Interna, Hospital Universitario Virgen de la Victoria, Campus de 
Teatinos, 29010 Málaga, Spain and 4Departamento de Bioestadística, Facultad 
de Medicina, Universidad de Málaga, Campus de Teatinos, 29010 Málaga, Spain
References
1. Visvikis-Siest S, Marteau JB: Genetic variants predisposing to 
cardiovascular disease.  Curr Opin Lipidol 2006, 17(2):139-51.
2. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, 
Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of 
coronary heart disease: 10,158 incident cases among 262,525 
participants in 29 Western prospective studies.  Circulation 2007, 
115(4):450-458.
3. Valdivielso P, Sanchez-Chaparro MA, Calvo-Bonacho E, Cabrera-Sierra M, 
Sainz-Gutierrez JC, Fernandez-Labandera C, Fernandez-Meseguer A, 
Quevedo-Aguado L, Moraga MR, Galvez-Moraleda A, Gonzalez-Quintela 
A, Roman-Garcia J, ICARIA (Ibermutuamur CArdiovascular RIsk Assesment) 
study group: Association of moderate and severe hypertriglyceridemia 
with obesity, diabetes mellitus and vascular disease in the Spanish 
working population: results of the ICARIA study.  Atherosclerosis 2009, 
207(2):573-578.
4. Morrison AC, Bare LA, Chambless LE, Ellis SG, Malloy M, Kane JP, Pankow 
JS, Devlin JJ, Willerson JT, Boerwinkle E: Prediction of coronary heart 
disease risk using a genetic risk score: the Atherosclerosis Risk in 
Communities Study.  Am J Epidemiol 2007, 166(1):28-35.
5. Merkel M, Eckel RH, Goldberg IJ: Lipoprotein lipase: genetics, lipid 
uptake, and regulation.  J Lipid Res 2002, 43(12):1997-2006.
6. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, 
Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in 
humans and mice revealed by comparative sequencing.  Science 2001, 
294(5540):169-73.
7. Merkel M, Heeren J: Give me A5 for lipoprotein hydrolysis!  J Clin Invest 
2005, 115(10):2694-6.
8. Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC: Is 
apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?  
Ann Med 2006, 38(1):2-10.
9. Mahley RW, C RS Jr: Apolipoprotein E: far more than a lipid transport 
protein.  Annu Rev Genomics Hum Genet 2000, 1:507-37.
10. Hara M, Iso ON, Satoh H, Noto H, Togo M, Ishibashi S, Kimura S, Kadowaki 
T, Hashimoto Y, Tsukamoto K: Differential effects of apolipoprotein E 
isoforms on lipolysis of very low-density lipoprotein triglycerides.  
Metabolism 2006, 55(8):1129-34.
11. Hu Y, Liu W, Huang R, Zhang X: A systematic review and meta-analysis of 
the relationship between lipoprotein lipase Asn291Ser variant and 
diseases.  J Lipid Res 2006, 47(9):1908-14.
12. Wittrup HH, Andersen RV, Tybjaerg-Hansen A, Jensen GB, Nordestgaard 
BG: Combined analysis of six lipoprotein lipase genetic variants on 
triglycerides, high-density lipoprotein, and ischemic heart disease: 
cross-sectional, prospective, and case-control studies from the 
Additional file 1 Primers and probes sequences and thermal cycling 
conditions used for DNA amplification and genotyping.
Additional file 2 Variant combinations observed in the study popula-
tion.
Received: 18 December 2009 Accepted: 29 April 2010 
Published: 29 April 2010
This article is available from: http://www.biomedcentral.com/1471-2350/11/66 © 2010 Ariza et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Medical Genetics 2010, 11:66Ariza et al. BMC Medical Genetics 2010, 11:66
http://www.biomedcentral.com/1471-2350/11/66
Page 10 of 10
Copenhagen City Heart Study.  J Clin Endocrinol Metab 2006, 
91(4):1438-45.
13. Chen Q, Razzaghi H, Demirci FY, Kamboh MI: Functional significance of 
lipoprotein lipase HindIII polymorphism associated with the risk of 
coronary artery disease.  Atherosclerosis 2008, 200(1):102-8.
14. Corella D, Guillen M, Saiz C, Portoles O, Sabater A, Folch J, Ordovas JM: 
Associations of LPL and APOC3 gene polymorphisms on plasma lipids 
in a Mediterranean population: interaction with tobacco smoking and 
the APOE locus.  J Lipid Res 2002, 43(3):416-27.
15. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, Stroes ES, 
Kuivenhoven JA: Lipoprotein lipase S447X: a naturally occurring gain-
of-function mutation.  Arterioscler Thromb Vasc Biol 2006, 26(6):1236-45.
16. Tang W, Apostol G, Schreiner PJ, Jacobs DR Jr, Boerwinkle E, Fornage M: 
Associations of Lipoprotein Lipase Gene Polymorphisms with 
Longitudinal Plasma Lipid Trends in Young Adults: the CARDIA Study.  
Circ Cardiovasc Genet 2010 in press.
17. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC: 
Two independent apolipoprotein A5 haplotypes influence human 
plasma triglyceride levels.  Hum Mol Genet 2002, 11(24):3031-8.
18. Hubacek JA: Apolipoprotein A5 and triglyceridemia. Focus on the 
effects of the common variants.  Clin Chem Lab Med 2005, 43(9):897-902.
19. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, 
Keavney B, Collins R, Wiman B, de Faire U, Danesh J: Association of 
apolipoprotein E genotypes with lipid levels and coronary risk.  Jama 
2007, 298(11):1300-11.
20. Polychronakos C: Common and rare alleles as causes of complex 
phenotypes.  Curr Atheroscler Rep 2008, 10(3):194-200.
21. Sanchez-Chaparro MA, Roman-Garcia J, Calvo-Bonacho E, Gomez-Larios T, 
Fernandez-Meseguer A, Sainz-Gutierrez JC, Cabrera-Sierra M, Garcia-
Garcia A, Rueda-Vicente J, Galvez-Moraleda A, Gonzalez-Quintela A: 
[Prevalence of cardiovascular risk factors in the Spanish working 
population].  Rev Esp Cardiol 2006, 59(5):421-30.
22. Sanchez-Chaparro MA, Calvo-Bonacho E, Gonzalez-Quintela A, 
Fernandez-Labandera C, Cabrera M, Sainz JC, Fernandez-Meseguer A, 
Banegas JR, Ruilope LM, Valdivielso P, Roman-Garcia J, Ibermutuamur 
Cardiovascular Risk Assessment (ICARIA) Study Group: Occupation-
related differences in the prevalence of metabolic syndrome.  Diabetes 
Care 2008, 31(9):1884-1885.
23. National Cholesterol Education Program  2007 [http://
www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf].
24. R Developement Core Team: R: A language and Environment for 
Satatistical Computing.  2008 [http://www.R-project.org]. R Fondation 
for Satatistical Computing, Vienna, Austria ISBN 3-900051-07-0
25. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, Moreno 
V: SNPassoc: an R package to perform whole genome association 
studies.  Bioinformatics 2007, 23(5):644-645.
26. Talmud PJ, Stephens JW: Lipoprotein lipase gene variants and the effect 
of environmental factors on cardiovascular disease risk.  Diabetes Obes 
Metab 2004, 6(1):1-7.
27. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase 
mutations, plasma lipids and lipoproteins, and risk of ischemic heart 
disease. A meta-analysis.  Circulation 1999, 99(22):2901-7.
28. Choumerianou DM, Maumus S, Skoumas J, Pitsavos C, Stefanadis C, 
Visvikis-Siest S, Dedoussis GV: Polymorphisms associated with 
apolipoprotein B levels in Greek patients with familial 
hypercholesterolemia.  Clin Chem Lab Med 2006, 44(7):799-806.
29. Chandak GR, Ward KJ, Yajnik CS, Pandit AN, Bavdekar A, Joglekar CV, Fall 
CH, Mohankrishna P, Wilkin TJ, Metcalf BS, Weedon MN, Frayling TM, 
Hattersley AT: Triglyceride associated polymorphisms of the APOA5 
gene have very different allele frequencies in Pune, India compared to 
Europeans.  BMC Med Genet 2006, 7:76.
30. Perez-Martinez P, Corella D, Shen J, Arnett DK, Yiannakouris N, Tai ES, 
Orho-Melander M, Tucker KL, Tsai M, Straka RJ, Province M, Kai CS, Perez-
Jimenez F, Lai CQ, Lopez-Miranda J, Guillen M, Parnell LD, Borecki I, 
Kathiresan S, Ordovas JM: Association between glucokinase regulatory 
protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms 
and triacylglycerol concentrations in fasting, postprandial, and 
fenofibrate-treated states.  Am J Clin Nutr 2009, 89(1):391-399.
31. Corella D, Guillen M, Saiz C, Portoles O, Sabater A, Cortina S, Folch J, 
Gonzalez JI, Ordovas JM: Environmental factors modulate the effect of 
the APOE genetic polymorphism on plasma lipid concentrations: 
ecogenetic studies in a Mediterranean Spanish population.  
Metabolism 2001, 50(8):936-44.
32. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ: Lipoprotein lipase 
gene variation is associated with a paternal history of premature 
coronary artery disease and fasting and postprandial plasma 
triglycerides: the European Atherosclerosis Research Study (EARS).  
Arterioscler Thromb Vasc Biol 1998, 18(4):526-34.
33. Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, 
Sans S, Do Carmo Martins M, De Backer G, Siest G, Visvikis S: The 
importance of plasma apolipoprotein E concentration in addition to its 
common polymorphism on inter-individual variation in lipid levels: 
results from Apo Europe.  Eur J Hum Genet 2002, 10(12):841-50.
34. Frikke-Schmidt R, Sing CF, Nordestgaard BG, Steffensen R, Tybjaerg-
Hansen A: Subsets of SNPs define rare genotype classes that predict 
ischemic heart disease.  Hum Genet 2007, 120(6):865-877.
35. Hubacek JA, Lanska V, Skodova Z, Adamkova V, Poledne R: Sex-specific 
interaction between APOE and APOA5 variants and determination of 
plasma lipid levels.  Eur J Hum Genet 2008, 16(1):135-138.
36. Hubacek JA, Horinek A, Skodova Z, Adamkova V, Ceska R, Zlatohlavek L, 
Vrablik M: Hypertriglyceridemia: interaction between APOE and APOAV 
variants.  Clin Chem 2005, 51(7):1311-3.
37. Sousa MO, Alia P, Pinto X, Corbella E, Navarro MA: Interaction between 
APOA5 -1131T>C and APOE polymorphisms and their association with 
severe hypertriglyceridemia.  Clin Chim Acta 2008, 395(1-2):68-71.
38. Brisson D, St-Pierre J, Santure M, Hudson TJ, Despres JP, Vohl MC, Gaudet 
D: Genetic epistasis in the VLDL catabolic pathway is associated with 
deleterious variations on triglyceridemia in obese subjects.  Int J Obes 
(Lond) 2007, 31(8):1325-1333.
39. Pitsavos C, Choumerianou DM, Skoumas J, Maumus S, Stefanadis C, 
Dedoussis GV, Visvikis-Siest S: Apolipoprotein E polymorphism is not 
associated with lipid levels and coronary artery disease in Greek 
patients with familial hypercholesterolaemia.  Clin Exp Med 2005, 
5(4):196-201.
40. Wang J, Ban MR, Zou GY, Cao H, Lin T, Kennedy BA, Anand S, Yusuf S, Huff 
MW, Pollex RL, Hegele RA: Polygenic determinants of severe 
hypertriglyceridemia.  Hum Mol Genet 2008, 17(18):2891-2899.
41. Ordovas JM, Tai ES: Why study gene-environment interactions?  Curr 
Opin Lipidol 2008, 19(2):158-67.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/66/prepub
doi: 10.1186/1471-2350-11-66
Cite this article as: Ariza et al., Additive effects of LPL, APOA5 and APOE vari-
ant combinations on triglyceride levels and hypertriglyceridemia: results of 
the ICARIA genetic sub-study BMC Medical Genetics 2010, 11:66